
Ipsen and Exelixis, partners in developing Cabometyx (cabozantinib), have revealed that they have cut short a Phase 3 trial into …

Celgene has already started off the year with a bang, announcing a deal with Impact Biomedicines worth a potential $7 …

When Peter Gassner, CEO and founder of Veeva, provided the keynote speech at the company’s European Commercial & Medical Summit, …

When PD-1/L1 treatments first came on the market, there was a race to snaffle as many indications as possible for …

Hikma Pharmaceuticals has announced that Surendera Tyagi is being brought in to join the company as Group Chief Scientific Officer …

A study created by researchers at the Centers for Disease Control and Prevention has estimated that asthma is costing the …

Real world evidence is high on the agenda at many conferences, as people mull over the possibilities that it may …

Just over a year ago, Teva closed a case with US authorities by agreeing to pay a $519 million fine …

Sanofi has agreed with the Department of Health (DoH) for the Philippines to reimburse $27.86 million worth of vaccines, though …

Vaccitech, a spin-out company from the University of Oxford, recently launched a Series A financing round and had some fairly …

The FDA has announced that it will require all labels to state that cough syrups containing codeine or hydrocodone are …

It’s been a terrible week for Alzheimer’s disease research, after Pfizer shuttered its neuroscience unit and

Novartis has been looking to find someone to fill the shoes of Bruno Strigini since it was revealed that he …

Teva’s current crisis is built upon problems that run deep into the company, after numerous acquisitions left it bloated and …

The AIDS Healthcare Foundation (AHF) has strongly criticised Gilead prices increases across the board for its HIV and AIDS treatment, …